Y-mabs names michael rossi as president and chief executive officer and director

New york, oct. 18, 2023 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced today that its board of directors has appointed michael rossi as president and chief executive officer (“ceo”) and a member of the board of directors with an expected start date of november 6, 2023. mr. rossi brings more than 30 years of experience in the radiopharmaceutical industry, including building out and leading the u.s. business for advanced accellerators applications (“aaa”), a novartis company, led the growth of jubilant radiopharm into a vertically integrated radiopharmaceutical leader, and spent after over a decade at ge healthcare and, more recently, served as president, medical group at mirion technologies, inc. (“mirion”). in connection with mr. rossi's appointment, thomas gad, who founded y-mabs in 2015 and has served as president and head of business development and strategy (since 2015) and interim ceo (since 2022) of the company, will cease serving in those offices and assume the roles of vice chairman of the board of directors and chief business officer of the company, in each case effective as of mr. rossi's start date.
YMAB Ratings Summary
YMAB Quant Ranking